

Amendments to the Specification

Please change the title to: Pharmaceutical compositions of isolated orthorhombic crystalline 4-[6-acetyl-3-[3-(4-acetyl-3-hydroxy-2-propylphenylthio)propoxy]-2-propylphenoxy]butyric acid and methods of use.

Amendments to the Claims

The following listing of claims replaces all prior versions of listing of claims in the application:

1. – 3. (Currently canceled)
4. (Previously canceled)
5. – 9. (Currently canceled)
10. (Previously canceled)
11. (Currently canceled)
12. (Previously canceled)
13. (New) A pharmaceutical composition comprising isolated orthorhombic crystalline 4-[6-acetyl-3-[3-(4-acetyl-3-hydroxy-2-propylphenylthio)propoxy]-2-propylphenoxy]butyric acid or a pharmaceutically acceptable salt or hydrate thereof together with a pharmaceutically acceptable carrier or excipient, which orthorhombic crystalline form (i) is substantially free of monoclinic crystalline forms as evidenced by powder x-ray diffraction (PXRD) analysis showing the absence of doublet peaks between about 11.5 and 16 (2-Theta scale), and (ii) exhibits at least twice the solubility of a monoclinic crystalline form at 30 °C in aqueous ethanol.
14. (New) The pharmaceutical composition of claim 13, which is formulated as a tablet.
15. (New) The pharmaceutical composition of claim 13, which is formulated as a capsule.

16. (New) The pharmaceutical composition of claim 13, which further comprises lactose and microcrystalline cellulose.
17. (New) The pharmaceutical composition of claim 14, which is a tablet weighing between 250 and 500 mg.
18. (New) Isolated orthorhombic crystalline 4-[6-acetyl-3-[3-(4-acetyl-3-hydroxy-2-propylphenylthio)propoxy]-2-propylphenoxy]butyric acid, which orthorhombic crystalline form (i) is substantially free of monoclinic crystalline forms as evidenced by powder x-ray diffraction (PXRD) analysis showing the absence of doublet peaks between about 11.5 and 16 (2-Theta scale), and (ii) exhibits at least twice the solubility of a monoclinic crystalline form at 30 °C in aqueous ethanol.
19. (New) A method of treating an allergic disease comprising administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising isolated orthorhombic crystalline 4-[6-acetyl-3-[3-(4-acetyl-3-hydroxy-2-propylphenylthio)propoxy]-2-propylphenoxy]butyric acid or a pharmaceutically acceptable salt or hydrate thereof, which orthorhombic crystalline form (i) is substantially free of monoclinic crystalline forms as evidenced by powder x-ray diffraction (PXRD) analysis showing the absence of doublet peaks between about 11.5 and 16 (2-Theta scale), and (ii) exhibits at least twice the solubility of a monoclinic crystalline form at 30 °C in aqueous ethanol.
20. (New) A method of claim 19 in which the allergic disease includes asthma.